The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 351-357

  Zivanovic, Oliver ^a   Sima, Camelia S ^a   Iasonos, Alexia ^a   Hoskins, William J ^a   Pingle, Pavani R ^a   Leitao Jr , Mario M M ^a   Sonoda, Yukio ^a   Abu Rustum, Nadeem R ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytoreduction; Ovarian cancer; Surgery; Survival; Upper abdominal disease; Upper abdominal disease cephalad to the greater omentum

Indexed keywords

PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GREATER OMENTUM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OMENTUM; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 75749085167     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.11.022     Document Type: Article

References (33)

1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Gynecologic Oncology Group: intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
2. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1001-1007
3. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
4. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., et al. Southwest Oncology Group; Gynecologic Oncology Group: phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
5. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C., et al. Gynecologic Oncology Group: secondary surgical cytoreduction for advanced ovarian carcinoma. N. Engl. J. Med. 351 (2004) 2489-2497
6. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
7. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
8. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol. Oncol. 103 (2006) 559-564
9. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 47 (1992) 203-209
10. Piver M.S., and Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol. Oncol. 24 (1986) 1-8
11. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., and Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 7 (1989) 457-465
12. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979 discussion 979-80
13. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 (1999) 278-287
14. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., and Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6 (1988) 983-989
15. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
16. Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J. Clin. Oncol. 25 (2007) 4168-4170
17. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 103 (2006) 1083-1090
18. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
19. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., and Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115 (2009) 1234-1244
20. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90 (2003) 390-396
21. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
22. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet. Gynecol. 107 (2006) 77-85
23. Aletti G.D., Dowdy S.C., Podratz K.C., and Cliby W.A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol. Oncol. 100 (2006) 283-287
24. Hoskins W.J., Bundy B.N., Thigpen J.T., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 (1992) 159-166
25. Crawford S.C., Vasey P.A., Paul J., Hay A., Davis J.A., and Kaye S.B. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J. Clin. Oncol. 23 (2005) 8802-8811
26. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecol. Oncol. 82 (2001) 435-441
27. Zivanovic O., Eisenhauer E.L., Zhou Q., Iasonos A., Sabbatini P., Sonoda Y., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 108 (2008) 287-292
28. Vergote I., Rustin G.J., Eisenhauer E.A., Kristensen G.B., Pujade-Lauraine E., Parmar M.K., et al. Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J. Natl. Cancer Inst. 92 (2000) 1534-1535
29. Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl. Cancer Inst. 96 (2004) 487-488
30. Lee E., Wei L., and Amato D. Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations (1992), Kluwer Academic Publishers 237-247
31. Eisenhauer E.L., D'Angelica M.I., Abu-Rustum N.R., Sonoda Y., Jarnagin W.R., Barakat R.R., et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol. Oncol. 103 (2006) 871-877
32. Kehoe S.M., Eisenhauer E.L., and Chi D.S. Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. Gynecol. Oncol. 111 suppl 2 (2008) S51-S55
33. Zivanovic O., Aldini A., Carlson J.W., and Chi D.S. Advanced cytoreductive surgery: American perspective. Gynecol. Oncol. 114 2 Suppl (2009) S3-S9